<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Response criteria for POEMS syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Response criteria for POEMS syndrome</h1>
<div class="graphic"><div class="figure"><div class="ttl">Response criteria for POEMS syndrome</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Parameter</td> <td class="subtitle1">Evaluable</td> <td class="subtitle1">Complete response</td> <td class="subtitle1">Improvement</td> <td class="subtitle1">Progression*</td> </tr> <tr> <td>Plasma VEGF</td> <td>2 × ULN</td> <td>Normal<sup>¶</sup></td> <td>50% reduction from baseline<sup>¶</sup></td> <td>50% increase from lowest level</td> </tr> <tr class="highlight_gray_text"> <td>Hematologic</td> <td>M-spike 0.5 g/dL<sup>Δ</sup>, 1.0 g/dL<sup>◊</sup><sup>§</sup></td> <td>Negative serum &amp; urine IFE &amp; bone marrow<sup>¶</sup></td> <td>50% reduction of M-spike from baseline<sup>¥</sup></td> <td>25% increase from lowest level, which must be &gt;0.5 g/dL</td> </tr> <tr> <td>PET/CT</td> <td>At least one lesion with FDG <span class="nowrap_whitespace">SUV<sub>max</sub><sup>‡</sup></span></td> <td>No FDG uptake</td> <td>50% reduction in sum of <span class="nowrap_whitespace">SUV<sub>max</sub><sup>‡</sup></span></td> <td>30% increase of sum of <span class="nowrap_whitespace">SUV<sub>max</sub><sup>‡</sup></span> from lowest level, which must be at least <span class="nowrap_whitespace">4 SUV<sub>max</sub><sup>‡</sup></span> <strong>OR</strong> appearance of new FDG avid lesion</td> </tr> <tr class="highlight_gray_text"> <td>mNIS +7<sub>POEMS</sub></td> <td>All patients</td> <td>–</td> <td><span class="arrow">↓</span>15% change from baseline (a minimum of 10 points)</td> <td><span class="arrow">↑</span>15% change from lowest value (a minimum of 10 points)</td> </tr> <tr> <td>Ascites/effusion/edema</td> <td>Present</td> <td>Absent</td> <td>Improved by 1 CTCAE grade from baseline</td> <td>Worsened by 1 CTCAE grade from lowest grade</td> </tr> <tr class="highlight_gray_text"> <td>ECHO RVSP</td> <td>≥40 mmHg</td> <td>–</td> <td>&lt;40 mmHg</td> <td>–</td> </tr> <tr> <td>Papilledema</td> <td>Present</td> <td>–</td> <td>Absent</td> <td>Worsening by 1 CTCAE grade</td> </tr> <tr class="highlight_gray_text"> <td>DLCO</td> <td>&lt;70% predicted</td> <td>≥70% predicted</td> <td>–</td> <td>Worsening by 1 CTCAE grade</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>POEMS: Polyneuropathy, Organomegaly, Endocrinopathy, M protein, Skin changes; DLCO: diffusing capacity of carbon monoxide; ECHO RVSP: echocardiogram right ventricular systolic pressure; IFE: immunofixation; PET/CT: positron emission tomography/computed tomography; mNIS+7: modified neuropathy impairment score + 7 neurophysiologic tests; CTCAE: common terminology criteria for adverse events.</p>
<p>* Any progression event (VEGF, hematologic, or clinical) will be considered progression, assuming change is attributable to disease and not an adverse event. To document progression, option exists for repeating value. If confirmed, progression date is first date of suspected progression.</p>
<p>¶ For VEGF and M-spike and IFE response documentation, blood values need to be repeated for verification.</p>
<p>Δ For VGPR evaluable.</p>
<p>◊ For PR evaluable.</p>
<p>§ Quantitative IgA is acceptable surrogate for M-spike for proteins migrating in the beta region.</p>
<p>¥ VGPR is defined as no measurable monoclonal protein on serum or urine electrophoresis, but positive IFE.</p>
‡ By body weight.</div><div class="graphic_reference">From: Dispenzieri A. POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management. Am J Hematol 2021; 96:872. <a href="https://onlinelibrary.wiley.com/doi/10.1002/ajh.26240" target="_blank">https://onlinelibrary.wiley.com/doi/10.1002/ajh.26240</a>. Copyright © 2021 Wiley Periodicals, LLC. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href="/cdn-cgi/l/email-protection#601005120d091313090f0e132017090c05194e030f0d"><span class="__cf_email__" data-cfemail="99e9fcebf4f0eaeaf0f6f7ead9eef0f5fce0b7faf6f4">[email protected]</span></a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href="https://onlinelibrary.wiley.com/" target="_blank">https://onlinelibrary.wiley.com/</a>).</div><div id="graphicVersion">Graphic 140899 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
